8-K: Cibus Reports First Quarter 2024 Financial Results and Provides Business Update

Cibus announced its first quarter 2024 financial results, highlighting commercial progress with its gene editing platform and advancements in regulatory approvals.

Summary

• Cibus reported its financial results for the first quarter of 2024, showing a net loss of $27.0 million, compared to a $5.4 million loss in the same period last year.
• The company's cash and cash equivalents stood at $24.5 million as of March 31, 2024.
• Cibus anticipates that its current cash reserves will fund operations into the third quarter of 2024, without considering potential financing activities.
• Research and development expenses increased significantly to $12.0 million, up from $2.2 million year-over-year, due to increased lab costs, headcount, and stock-based compensation.
• Selling, general, and administrative expenses also rose to $7.0 million, compared to $2.3 million in the prior year, driven by increased headcount, consulting fees, and stock-based compensation.
• The company signed three agreements for its herbicide tolerance traits in rice, including with Loveland Products Inc. and Interoc S.A.
• Cibus has completed its single-cell regeneration platform for wheat, marking a significant breakthrough.
• The EU Parliament's vote to support gene editing regulations similar to conventional breeding is seen as a positive development for the industry.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in technology and commercialization, the significant increase in net loss and the need for additional funding temper the overall sentiment. The regulatory progress in the EU is a positive sign, but the financial challenges are concerning.

Positives

• Cibus has made significant commercial progress by securing multiple agreements for its herbicide tolerance traits in rice.
• The successful completion of the wheat single-cell regeneration platform is a major technological achievement.
• The EU Parliament's vote is a positive regulatory development that could open new markets for Cibus' technology.
• Cibus is advancing its pod shatter reduction trait in canola with ongoing field trials in the UK.
• The company is expanding its platform to include soybean, which is a large addressable market.
• Cibus has been recognized as one of the world's most innovative companies.

Negatives

• Cibus reported a significant net loss of $27.0 million for the quarter, a substantial increase from the $5.4 million loss in the same period last year.
• The company's operating expenses, particularly in research and development and selling, general, and administrative, have increased significantly.
• The company's cash reserves are expected to fund operations only into the third quarter of 2024, necessitating potential financing activities.
• The royalty liability interest expense from related parties was a significant non-cash expense of $8.3 million.

Risks

• Cibus needs additional near-term funding to finance its activities and faces challenges in obtaining additional capital.
• There are risks associated with the commercialization of Cibus' traits, including farmer adoption and market acceptance.
• Regulatory developments could disfavor or impose burdens on gene-editing processes or products.
• The company faces competition and risks related to intellectual property protection.
• There are risks associated with the possible failure to realize certain anticipated benefits of the Merger Transactions.

Future Outlook

Cibus expects its current cash reserves to fund operations into the third quarter of 2024, without considering potential financing activities. The company anticipates several development and commercial milestones in 2024, including expanding its customer base, achieving greenhouse results for advanced traits, and operationalizing its soybean platform.

Management Comments

• We are off to a great start in 2024 with the commercialization of our platform, technology and products, stated Rory Riggs, Co-Founder, Chairman, and CEO of Cibus.
• The combination of our product development and advancement toward scalable commercialization advances our vision to become the leader in agricultural gene editing, working alongside seed companies to help farmers address their sustainability, productivity and environmental challenges at a fraction of the time and cost of conventional breeding or GMO methods.
• These developments combined with the favorable advancements in the global regulatory landscape have Cibus well positioned to make a measurable impact on the industry.

Industry Context

The announcement comes amid increasing global momentum for the approval of new genomic techniques, particularly in major agricultural markets. The EU's shift towards regulating gene-edited products similarly to conventional breeding is a significant development that could accelerate the adoption of Cibus' technology. This is in line with a broader trend of using gene editing to improve crop yields and sustainability.

Comparison to Industry Standards

• Cibus' focus on high-throughput gene editing aligns with the industry's move towards faster and more efficient breeding methods, similar to companies like Pairwise and Benson Hill.
• The successful regeneration of wheat plants from single cells is a significant achievement, comparable to advancements in other crop gene editing platforms.
• The company's strategy of licensing traits to seed companies is a common approach in the agricultural biotech industry, similar to how companies like Corteva and Bayer operate.
• Cibus' focus on productivity traits such as herbicide tolerance and disease resistance is consistent with industry trends aimed at addressing key challenges faced by farmers globally.
• The company's progress in securing agreements with major seed companies like Nutrien and Interoc is a positive sign of market acceptance, similar to how other biotech companies establish partnerships for commercialization.

Management Changes

Related Party Transactions

• Royalty liability interest expense related parties was $8.3 million for the quarter ended March 31, 2024.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for additional financing.
• Employees may be impacted by the company's cost-saving initiatives.
• Customers (seed companies) will benefit from the new traits and technologies being developed by Cibus.
• Suppliers may see increased business as Cibus expands its operations.
• Creditors may be concerned about the company's financial performance and need for additional capital.

Next Steps

• Cibus expects 8 of 10 PSR customers in Canola to have their elite germplasm edited with Cibus' trait either transferred to the customer or ready to be transferred to the customer.
• The company expects to collect HT3 field testing data for Rice in Latin America.
• Cibus plans to expand its customer base with existing developed productivity traits.
• The company expects greenhouse results for a third mode of action for Sclerotinia resistance.
• Cibus expects greenhouse results for HT2.
• The company expects its Soybean single-cell regeneration platform to be operational and have initial editing completed.
• Cibus plans to initiate the first edits toward developing traits for Wheat.
• The company expects to enter into initial development/commercial agreements related to Wheat.
• Cibus will continue progress to develop sustainable low carbon ingredients or materials for the consumer packaged goods industry.

Key Dates

Keywords

gene editing, agricultural biotechnology, plant traits, herbicide tolerance, pod shatter reduction, wheat, rice, canola, soybean, sclerotinia resistance, commercialization, regulatory approval, RTDS, Trait Machine